Johnson & Johnson Total Assets 2010-2024 | JNJ
Johnson & Johnson total assets from 2010 to 2024. Total assets can be defined as the sum of all assets on a company's balance sheet.
- Johnson & Johnson total assets for the quarter ending March 31, 2024 were $167.558B, a 10.58% decline year-over-year.
- Johnson & Johnson total assets for 2023 were $167.558B, a 10.58% decline from 2022.
- Johnson & Johnson total assets for 2022 were $187.378B, a 2.94% increase from 2021.
- Johnson & Johnson total assets for 2021 were $182.018B, a 4.07% increase from 2020.
Johnson & Johnson Annual Total Assets
(Millions of US $) |
| 2023 |
$167,558 |
| 2022 |
$187,378 |
| 2021 |
$182,018 |
| 2020 |
$174,894 |
| 2019 |
$157,728 |
| 2018 |
$152,954 |
| 2017 |
$157,303 |
| 2016 |
$141,208 |
| 2015 |
$133,411 |
| 2014 |
$130,358 |
| 2013 |
$132,683 |
| 2012 |
$121,347 |
| 2011 |
$113,644 |
| 2010 |
$102,908 |
| 2009 |
$94,682 |
Johnson & Johnson Quarterly Total Assets
(Millions of US $) |
| 2023-12-31 |
$167,558 |
| 2023-09-30 |
$166,061 |
| 2023-06-30 |
$191,686 |
| 2023-03-31 |
$195,969 |
| 2022-12-31 |
$187,378 |
| 2022-09-30 |
$175,124 |
| 2022-06-30 |
$177,724 |
| 2022-03-31 |
$178,355 |
| 2021-12-31 |
$182,018 |
| 2021-09-30 |
$179,228 |
| 2021-06-30 |
$176,440 |
| 2021-03-31 |
$172,557 |
| 2020-12-31 |
$174,894 |
| 2020-09-30 |
$170,693 |
| 2020-06-30 |
$158,380 |
| 2020-03-31 |
$155,017 |
| 2019-12-31 |
$157,728 |
| 2019-09-30 |
$155,521 |
| 2019-06-30 |
$155,117 |
| 2019-03-31 |
$150,027 |
| 2018-12-31 |
$152,954 |
| 2018-09-30 |
$155,703 |
| 2018-06-30 |
$155,365 |
| 2018-03-31 |
$156,625 |
| 2017-12-31 |
$157,303 |
| 2017-09-30 |
$155,658 |
| 2017-06-30 |
$152,807 |
| 2017-03-31 |
$144,918 |
| 2016-12-31 |
$141,208 |
| 2016-09-30 |
$140,369 |
| 2016-06-30 |
$139,814 |
| 2016-03-31 |
$136,231 |
| 2015-12-31 |
$133,411 |
| 2015-09-30 |
$133,266 |
| 2015-06-30 |
$132,036 |
| 2015-03-31 |
$128,590 |
| 2014-12-31 |
$130,358 |
| 2014-09-30 |
$132,097 |
| 2014-06-30 |
$135,200 |
| 2014-03-31 |
$133,330 |
| 2013-12-31 |
$132,683 |
| 2013-09-30 |
$126,933 |
| 2013-06-30 |
$124,325 |
| 2013-03-31 |
$121,536 |
| 2012-12-31 |
$121,347 |
| 2012-09-30 |
$118,951 |
| 2012-06-30 |
$115,750 |
| 2012-03-31 |
$116,194 |
| 2011-12-31 |
$113,644 |
| 2011-09-30 |
$111,821 |
| 2011-06-30 |
$112,114 |
| 2011-03-31 |
$108,150 |
| 2010-12-31 |
$102,908 |
| 2010-09-30 |
$98,247 |
| 2010-06-30 |
$92,300 |
| 2010-03-31 |
$93,441 |
| 2009-12-31 |
$94,682 |
| 2009-09-30 |
$91,558 |
| 2009-06-30 |
$87,438 |
| 2009-03-31 |
$86,100 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$356.431B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
